HK Stock Market Move | Z.AI (02513) rose nearly 7% in morning trading as the market speculates that Z.AI GLM-5.5 is about to be released.
Z.AI (02513) rose nearly 7% in morning trading. As of press time, it was up 3.36% at HK$569, with turnover of HK$1.827 billion.
Z.AI (02513) rose nearly 7% in morning trading. As of press time, it was up 3.36% at HK$569, with turnover of HK$1.827 billion.
On the news front, on October 15, Tsinghua University and Z.AI's Tang Jie team published a new paper on arXiv. Although the paper did not disclose the version correspondence, it presented the technical foundation of GLM-Omni and a set of experimental results on unified visual understanding and image generation. The market speculates that GLM-5.5 is about to be released. In addition, OpenCode has already posted a GLM-5.5 Flash page.
It is worth noting that Anthropic plans to hold an IPO in the week of November 16, with a target valuation of up to US$2 trillion. If successfully completed, it would become the largest IPO in history. CITIC SEC released a research report stating that although the current market attitude toward large models has become more cautious, it remains firmly bullish on the long-term commercial value and valuation growth space of Chinese and U.S. models.
Related Articles

HK Stock Market Move | Montage Technology (06809) rose more than 9% in early trading; peer Rambus posted strong results and guidance; BofA says this is positive news for Montage

HK Stock Market Move | InnoCare Pharma (09969) rises over 4%, turns profitable in the first three quarters, with core product orelabrutinib continuing to ramp up sales.
.png)
Goldman Sachs: Raises WuXi AppTec (02359) H-share target price to HK$251, maintains "Buy" rating
HK Stock Market Move | Montage Technology (06809) rose more than 9% in early trading; peer Rambus posted strong results and guidance; BofA says this is positive news for Montage

HK Stock Market Move | InnoCare Pharma (09969) rises over 4%, turns profitable in the first three quarters, with core product orelabrutinib continuing to ramp up sales.

Goldman Sachs: Raises WuXi AppTec (02359) H-share target price to HK$251, maintains "Buy" rating
.png)





